LIC MF Healthcare Fund Direct-Growth
Equity: Sectoral-Pharma - Growth (Open ended)
SEBI Riskometer: Very HighCategory: Equity: Sectoral-PharmaBenchmark: BSE Healthcare Total Return IndexCheck Portfolio Overlap →
NAV: ₹34.63+0.02%
22 Oct 2026
Holdings Analysis
Equity, debt and cash allocation snapshot with market cap distribution for LIC MF Healthcare Fund Direct-Growth.
Market Cap Distribution
Large Cap (31.2%)
Mid Cap (32.8%)
Small Cap (36.0%)
Historical Asset Allocation
| Asset | 30 Sep 2026 | 31 Aug 2026 | 31 Jul 2026 | 30 Jun 2026 | 31 May 2026 | 30 Apr 2026 |
|---|---|---|---|---|---|---|
| Equity | 97.53% | 98.52% | 96.93% | 95.19% | 92.92% | 96.12% |
| Debt | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Others (incl. cash) | 2.47% | 1.48% | 3.07% | 4.81% | 7.08% | 3.88% |
| Commodities | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Real Estate | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Portfolio Snapshot
No. of Securities
26
P/E Ratio
52.00
P/B Ratio
6.02
Top Holding %
9.59%
Top 5 Holdings %
36.59%
Top 10 Holdings %
60.15%
AUM
₹99 Cr
Expense Ratio
1.38%
Since Inception
17.62%
Max Drawdown
-0.22%
Alpha
0.44%
Sharpe Ratio
0.91
Top Portfolio Holdings by Weight
Latest portfolio holdings sorted by allocation weight. Includes instrument name, sector, number of shares, market value (₹ Cr) and percentage of net assets. Switch dates or categories using the controls below.
| Instrument | Sector | No. of Shares | Value (Rs. Cr) | Weight | Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | Healthcare | 52,436 | 9.53 | 9.59% | -0.50%↓ |
| Divis Laboratories Ltd. | Healthcare | 9,700 | 9.01 | 9.07% | -0.22%↓ |
| Neuland Laboratories Ltd. | Healthcare | 2,859 | 6.1 | 6.14% | -0.24%↓ |
| Torrent Pharmaceuticals Ltd. | Healthcare | 12,500 | 6 | 6.04% | -0.41%↓ |
| Apollo Hospitals Enterprise Ltd. | Healthcare | 7,000 | 5.72 | 5.75% | -0.48%↓ |
| Aurobindo Pharma Ltd. | Healthcare | 31,050 | 5.19 | 5.23% | 0.06%↑ |
| Navin Fluorine International Ltd. | Chemicals | 6,000 | 4.95 | 4.98% | -0.67%↓ |
| Zydus Lifesciences Ltd. | Healthcare | 42,500 | 4.94 | 4.97% | 0.18%↑ |
| Aster DM Quality Care Ltd. | Healthcare | 65,750 | 4.58 | 4.61% | -0.21%↓ |
| Fortis Healthcare Ltd. | Healthcare | 48,600 | 3.74 | 3.77% | -0.01%↓ |
| Metropolis Healthcare Ltd. | Healthcare | 61,500 | 3.33 | 3.35% | 0.18%↑ |
| Gland Pharma Ltd. | Healthcare | 10,977 | 3.18 | 3.20% | -0.73%↓ |
| Mankind Pharma Ltd. | Healthcare | 12,327 | 3.09 | 3.11% | 0.22%↑ |
| Nephrocare Health Services Ltd. | Healthcare | 46,000 | 3.03 | 3.05% | - |
| Max Healthcare Institute Ltd. | Healthcare | 32,000 | 2.98 | 2.99% | 0.44%↑ |
| Cohance Lifesciences Ltd. | Healthcare | 65,950 | 2.93 | 2.95% | 0.03%↑ |
| Glenmark Pharmaceuticals Ltd. | Healthcare | 11,100 | 2.59 | 2.61% | -0.27%↓ |
| Global Health Ltd. | Healthcare | 18,879 | 2.58 | 2.59% | -0.60%↓ |
| Dr. Agarwals Health Care Ltd. | Healthcare | 51,001 | 2.44 | 2.46% | -0.08%↓ |
| Biocon Ltd. | Healthcare | 63,500 | 2.35 | 2.37% | -0.17%↓ |
1 / 2
Sector-wise Portfolio Allocation
Equity exposure by sector as a percentage of total net assets, tracked across recent portfolio dates. Identifies concentration risk and sector rotation trends in the fund's holdings.
| Sector | 30 Sep 2026 | 31 Aug 2026 | 31 Jul 2026 | 30 Jun 2026 | 31 May 2026 | 30 Apr 2026 |
|---|---|---|---|---|---|---|
| Healthcare | 92.55% | 92.87% | 91.73% | 89.61% | 87.54% | 91.43% |
| Chemicals | 4.98% | 5.65% | 5.20% | 5.58% | 5.38% | 4.69% |
Equity Insights
A detailed look at the equity holdings of this scheme — aggregated scores on value, momentum, quality parameters along with diversification and performance analysis.
Style Analysis
Value score
25.1 / 100
Weighted average Value score is 25.1. This indicates that portfolio is relatively reasonably valued using composite of value measures.
Price Momentum score
73.8 / 100
Weighted average Price Momentum score is 73.8. This indicates that portfolio has average momentum using composite of momentum measures.
Quality score
85.7 / 100
Weighted average Quality score is 85.7. This indicates that portfolio has high quality using composite of quality measures.
QVM score
71.6 / 100
Weighted average QVM score is 71.6. This indicates that portfolio has average QVM score and hence a neutral stance is warranted.
Red Flags
Frequently Asked Questions
What are the top holdings of LIC MF Healthcare Fund Direct-Growth?
The top holdings of LIC MF Healthcare Fund Direct-Growth as of 30 Sep 2026 are Sun Pharmaceutical Industries Ltd. (9.59%), Divis Laboratories Ltd. (9.07%), Neuland Laboratories Ltd. (6.14%), Torrent Pharmaceuticals Ltd. (6.04%), Apollo Hospitals Enterprise Ltd. (5.75%). These top 5 stocks together account for 36.59% of the total portfolio. You can view the complete holdings breakdown above.
How many stocks does LIC MF Healthcare Fund Direct-Growth hold in its portfolio?
LIC MF Healthcare Fund Direct-Growth holds 26 stocks in its portfolio as of 30 Sep 2026. The fund's portfolio size reflects the fund manager's investment approach, a more concentrated portfolio indicates higher conviction bets, while a larger number of holdings suggests a more diversified strategy.
What is the sector allocation of LIC MF Healthcare Fund Direct-Growth?
As of 30 Sep 2026, LIC MF Healthcare Fund Direct-Growth's top sector allocations are Healthcare (92.55%), Chemicals (4.98%). You can find detailed sector allocation above.
What is the equity and debt allocation of LIC MF Healthcare Fund Direct-Growth?
As of 30 Sep 2026, LIC MF Healthcare Fund Direct-Growth has 97.53% allocated to equity, and 0.00% to debt. You can also check the historical trends above.
What is the market cap allocation of LIC MF Healthcare Fund Direct-Growth?
As of 30 Sep 2026, LIC MF Healthcare Fund Direct-Growth's market cap allocation is 31.22% in large caps, 32.80% in mid caps, and 35.98% in small caps.
What is the PE ratio of LIC MF Healthcare Fund Direct-Growth's portfolio?
The portfolio PE ratio of LIC MF Healthcare Fund Direct-Growth is 52.00 as of 30 Sep 2026. The portfolio PE ratio tells you how expensive or cheap the fund's holdings are relative to their earnings.
What is the credit quality of LIC MF Healthcare Fund Direct-Growth?
A credit rating breakdown is not available for LIC MF Healthcare Fund Direct-Growth — its non-equity allocation was 0.00% as of the latest disclosure. This is common when a fund's non-equity holdings are mostly cash or short-term money market instruments, which aren't assigned a credit rating the way bonds are.
When is the latest portfolio disclosure for LIC MF Healthcare Fund Direct-Growth?
The latest portfolio disclosure for LIC MF Healthcare Fund Direct-Growth is as of 30 Sep 2026. SEBI requires all mutual funds to disclose their complete portfolio holdings on a monthly basis, typically within 10 days of the end of each month.